![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Feder, K.; Edmaier, K.; Eshraghi, P.; Vegi, N.; Mulaw, M.; Ihme, S.; Spiekermann, K.; Metzeler, K.; Hiddemann, W.; Döhner, K.; Döhner, H.; Feuring-Buske, M. und Buske, C.
(2016):
The Lef1 isoform, lacking the β-catenin binding domain, is not acting as a dominant negative Lef1 variant, but is a hematopoietic active protein with unique DNA binding properties.
In: Oncology Research and Treatment, Bd. 39: S. 46
Schneider, F.; Hoster, Eva; Schneider, S.; Dufour, A.; Benthaus, T.; Kakadia, P. M.; Bohlander, Stefan K.; Braess, J.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Feuring-Buske, M.; Buske, C.; Creutzig, U.; Thiede, C.; Zwaan, M. C.; Heuvel-Eibrink, M. M. van den; Reinhardt, D.; Hiddemann, Wolfgang und Spiekermann, Karsten
(2012):
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
In: Annals of Hematology, Bd. 91, Nr. 1: S. 9-18
Schneider, F.; Hoster, Eva; Unterhalt, Michael; Schneider, S.; Dufour, A.; Benthaus, T.; Mellert, G.; Zellmeier, Evelyn; Kakadia, P. M.; Bohlander, Stefan K.; Feuring-Buske, M.; Buske, C.; Braess, J.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Hiddemann, Wolfgang und Spiekermann, Karsten
(2012):
The FLT3ITD level has a high prognostic impact in NPM1 mutated, but not NPM1 unmutated AML with a normal karyotype.
In: Blood, Bd. 119, Nr. 19: S. 4383-4386
Herold, Tobias; Jurinovic, Vindi; Metzeler, Klaus H.; Boulesteix, Anne-Laure; Bergmann, M.; Seiler, T.; Mulaw, M.; Thoene, S.; Dufour, A.; Pasalic, Z.; Schmidberger, Markus; Schmidt, M.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K.
(2011):
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia.
In: Leukemia, Bd. 25, Nr. 10: S. 1639-1645
Herold, Tobias; Jurinovic, Vindi; Mulaw, M.; Seiler, T.; Dufour, A.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K.
(2011):
Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20.
In: Genes, Chromosomes and Cancer, Bd. 50, Nr. 7: S. 546-558
Thoene, S.; Rawat, V. P.; Heilmeier, B.; Hoster, Eva; Metzeler, Klaus H.; Herold, Tobias; Hiddemann, Wolfgang; Gökbuget, Nicola; Hoelzer, D.; Bohlander, Stefan K.; Feuring-Buske, M. und Buske, C.
(2009):
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia.
In: Leukemia, Bd. 23, Nr. 4: S. 649-655
Schneider, F.; Hoster, Eva; Unterhalt, Michael; Schneider, S.; Dufour, A.; Benthaus, T.; Mellert, G.; Zellmeier, Evelyn; Bohlander, Stefan K.; Feuring-Buske, M.; Buske, C.; Braess, J.; Fritsch, S.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Hiddemann, Wolfgang und Spiekermann, Karsten
(2009):
NPM1, but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high risk myelodysplastic syndrome (MDS).
In: Blood, Bd. 113, Nr. 21: S. 5250-5253